Published in J Infect Dis on June 16, 2014
Select host restriction factors are associated with HIV persistence during antiretroviral therapy. AIDS (2015) 0.81
CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy. J Infect Dis (2015) 0.77
Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation. PLoS Pathog (2016) 0.76
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science (1997) 15.12
The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med (1996) 10.62
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med (2014) 7.64
HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med (2011) 6.30
Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood (2010) 4.99
Highly precise measurement of HIV DNA by droplet digital PCR. PLoS One (2013) 3.53
T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis (2011) 3.38
Identification of direct genomic targets downstream of the nuclear factor-kappaB transcription factor mediating tumor necrosis factor signaling. J Biol Chem (2005) 2.43
Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol (2002) 2.32
Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis (2013) 2.23
Cell-associated HIV RNA: a dynamic biomarker of viral persistence. Retrovirology (2013) 1.37
Human immunodeficiency virus type 1 RNA Levels in different regions of human brain: quantification using real-time reverse transcriptase-polymerase chain reaction. J Neurovirol (2007) 1.30
Immunogenetics of HIV disease. Immunol Rev (2013) 1.25
No evidence for an effect of the CCR5 delta32/+ and CCR2b 64I/+ mutations on human immunodeficiency virus (HIV)-1 disease progression among HIV-1-infected injecting drug users. J Infect Dis (1999) 1.03
Weighing the risk of drug resistance with the benefits of HIV preexposure prophylaxis. J Infect Dis (2015) 0.87